Figure 1.

MYCN/BCL2 promotes the contribution of hPSCs in teratoma co-formation mixed with mESCs

(A) Schematic overview of co-differentiation of hPSCs-dsRed and mESCs-GFP in vivo. hPSCs-dsRed and mESCs-GFP are initially mixed in 1:1 ratio at the single-cell level for further differentiation.

(B and C) The teratoma formed by the mixture of hPSCs-dsRed and mESCs-GFP at 4 weeks. dsRed-labeled human cells in teratoma were analyzed by flow cytometry. Scale bars, 2 mm.

(D) Analysis of MYC and MYCN expression in the indicated cells by qRT-PCR. Error bars represent mean + SEM of three parallel experiments. ^∗∗∗p < 0.001.

(E) The morphology of BCL2- or MYCN/BCL2-expressed hPSCs. Scale bars, 100 μm.

(F) Teratomas formed by B-hPSCs or M/B-hPSCs mixed with mESCs in 1:1 ratio. Scale bars, 2 mm.

(G) Flow cytometry analysis of dsRed-labeled human cells in indicated teratomas. Error bars represent mean + SEM of three independent replicates. ^∗∗∗p < 0.001.

(H) Immunohistochemical analysis of human cells in indicated teratomas with human-specific anti-Stem121 antibody. Scale bars, 1 mm.

(I) H&E staining of teratomas formed by B-hPSCs or M/B-hPSCs mixed with mESCs in 1:1 ratio. Three typical germ layers are shown. Scale bars, 50 μm.